Dutasteride

Dutasteride is used for benign prostatic hyperplasia. If proposed for hair loss, the clinician should explain the off-label rationale and how the hair-loss diagnosis was established. A product containing dutasteride plus minoxidil and vitamins requires separate evaluation of the complete formulation. ¹

Sexual symptoms, breast changes and fertility concerns are relevant. Pregnancy exposure is important, including contact with leaking capsules. Dutasteride can affect interpretation of prostate-specific antigen testing; the clinician interpreting results needs to know about treatment. Blood donation restrictions after treatment ends also require product-specific advice. ¹

Bring the actual product label, other hormone-active medicines, fertility plans and any prior hair-loss treatment. Ask why dutasteride is preferred, what evidence applies to the proposed route, how adverse effects will be reviewed, and what would prompt a change.

Dutasteride remains in the body for a long time after the last capsule, which matters for adverse effects, pregnancy exposure and blood donation. People who are or may be pregnant should not handle leaking capsules because the drug can be absorbed through skin and may harm a male fetus. Follow the label's blood-donation restriction after stopping. Fertility goals, semen changes and sexual adverse effects should be discussed before treatment rather than inferred from a single hormone test. ¹

Dutasteride lowers PSA, so the clinician interpreting prostate testing needs the start date, adherence and current product. A new rise from the lowest value can require assessment even if the number remains within a general reference range. The medicine does not replace evaluation of urinary obstruction, infection, blood in urine or cancer risk. New breast lumps, nipple discharge, testicular symptoms or a sudden inability to urinate also deserve prompt review. ¹

Use for scalp hair loss is off-label in the United States. A capsule, topical preparation and combination with minoxidil are different interventions. Ask what evidence applies to the selected route, how systemic exposure will be monitored, and what household-transfer precautions apply. Because dutasteride persists, stopping does not immediately remove exposure. Do not combine it with finasteride simply because both affect DHT; overlapping therapy needs a clinician's explicit rationale and safety plan. ¹

Swallow capsules whole; opening or chewing them can expose the mouth and skin to the contents. A leaking capsule should not be handled by someone who is or may be pregnant. If contact occurs, wash the area with soap and water and seek product-specific advice. Store capsules securely away from children and do not share them, even when another person has similar urinary or hair concerns. ¹